We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Pneumocystis Frequently Found Lethal in Dermatomyositis

By LabMedica International staff writers
Posted on 25 Sep 2021
Print article
Photomicrograph of Pneumocystis jirovecii cysts in stained with Grocott-Gomori Methenamine special silver stain of lung epithelium shows numerous small, disk-shaped organisms (Photo courtesy of Michelle N Kelly, PhD,  and Judd E Shellito, MD)
Photomicrograph of Pneumocystis jirovecii cysts in stained with Grocott-Gomori Methenamine special silver stain of lung epithelium shows numerous small, disk-shaped organisms (Photo courtesy of Michelle N Kelly, PhD, and Judd E Shellito, MD)
The term idiopathic inflammatory myopathy (IIM) denotes a group of autoimmune diseases characterized by myasthenia and typical skin rash, among which dermatomyositis (DM) and polymyositis (PM) are the most common.

Idiopathic inflammatory myopathies (IIM) are associated with a significantly higher risk of opportunistic infections including Pneumocystis jirovecii pneumonia (PJP), a potentially fatal opportunistic infection. In patients with rheumatic immune diseases, most PJP occurs in the first three months after initiating immunosuppressive therapy.

A team of Rheumatologists at the Renji Hospital (Shanghai, China) prospectively followed 463 consecutive patients with IIM a period of at least one year to analyze the incidence of PJP. In the second part of the study, they enrolled 30 consecutive PJP patients with any rheumatic disease in order to identify the mortality rate and risk factors. The diagnosis of PJP was based on comprehensive evaluation by clinical manifestations such as fever or acute dyspnea, characteristic radiographic findings, and etiological evidence. For confirmation, a case needed to have positive microbiological tests such as by next-generation sequencing and Grocott-Gomori methenamine-silver staining of bronchoalveolar lavage fluid.

The team reported that the prevalence of PJP in IIM patients was found to be 3.0/100 person-years, while in anti-melanoma differentiation-associated gene 5 antibody positive (MDA5+) DM patients it was 7.5/100 person-years and in MDA5− IIM patients 0.7/100 person-years. PJP typically occurred in the first two months in the case of MDA5+ DM patients who had a significant decrease in their CD4+ T cell counts and lymphocyte counts. In PJP patients, 3-month mortality was higher for MDA5+ DM patients than in those with other rheumatic diseases (83.3% versus 38.9%). Worryingly, MDA5+ DM patients seemed not to benefit from prompt anti-PJP treatment, unlike patients with other rheumatic diseases whose survival improved when anti-PJP treatment was started within six days.

The authors concluded that the MDA5+ DM patients are highly susceptible to infection with Pneumocystis jirovecii, which is also harder to cure than in other rheumatic diseases. The reason for the higher incidence and mortality may be related to the lower CD4+ T cell counts and progressive interstitial lung disease in MDA5+ patients. The study was published on September 4, 2021 in the journal Arthritis Research & Therapy.

Related Links:

Renji Hospital

New
Gold Supplier
Pipette Tips
Sapphire Pipette Tips
New
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
Real Time PCR Platform
VIASURE V-Lab96
New
Cardiovascular Disease POC Analyzer
cobas h 232 POC System

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.